Drug Profile
Bevacizumab biosimilar - Beijing Mabworks Biotech
Alternative Names: MIL 60Latest Information Update: 24 Jun 2022
Price :
$50
*
At a glance
- Originator Beijing Mabworks Biotech; Betta Pharmaceuticals Co Ltd
- Class Antineoplastics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Cervical cancer; Colorectal cancer; Fallopian tube cancer; Glioblastoma; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer
- Preregistration Liver cancer